🔗 Share this article

As the US undertakes unprecedented revisions to its vaccine recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines throughout the global health crisis and has focused upon possible fatalities after COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Program

Agency leaders were set to unveil sweeping revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with many the international standard with no evidence for benefit. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A New Direction at the FDA

This interim role could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending specific pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

Høeg has no obvious track record in medication creation, oversight or leadership, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Previous heads of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who ran CBER have had.”

This division has an enormous portfolio at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the generic drug division approves a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these have to be managed,” Dr. Woodcock said. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the role, which manages more than 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” she added.

Response and Controversial Programs

In response to inquiries about Høeg’s credentials and whether this appointment represents greater collaboration among agency officials on immunizations, a press secretary said that the “inquiries stem from inaccurate presumptions”.

“Her experience matches the responsibilities of her role,” the official said, noting the period Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed expedited medication authorization process that allegedly concerned her predecessors. “How are these drugs being chosen for this voucher program? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards more relaxed regulations of most medications, with the exception of shots.”

Public History on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, track record, Howard said. She released a research paper using unconfirmed crowd-sourced reports to determine the frequency of myocarditis following Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the incoming government featured revising regulations for novel immunizations and discontinuing “non-essential” immunizations, she remarked post-election on a audio program. At the agency, Høeg has according to sources suggested preventing adolescent males from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her preconceived notions and tailors the evidence to retrofit the data in a extremely disingenuous, untruthful manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|